Merck appoints committee to review company actions on Vioxx
623702
Beleaguered pharmaceutical giant Merck &amp; Co. Inc. has appointed a special committee of board members and a retired federal judge to review the company&#39;s actions before it
332433
Merck&#39;s (MRK :NYSE - news - research) decision to withdraw its popular arthritis drug Vioxx from the market in late September has raised questions about the process leading up to its regulatory approval in 1999 as well as the importance of subsequent
455038
U.S. regulators said on Friday they would review whether to take action over Merck & Co Inc's and Schering-Plough Corp's popular cholesterol drug Vytorin after a study showed it was no better than a generic in preventing the build-up of fatty plaque.
679017
A week after saying it was withdrawing its $2.5 billion arthritis drug Vioxx from the market and losing a quarter of its stock market value as a result, Merck &amp; Co. will try to dodge the storm clouds and turn its attention tomorrow to a brighter subject with the official opening of its Boston research lab.
131481
Nov. 5, 2004 -- FDA officials announced Friday that they will launch a review of the agency&#39;s drug monitoring policies in the wake of recent high-profile safety concerns about widely used drugs, including antidepressants and Vioxx.
45750
The Food and Drug Administration told Merck &amp; Co. that it would approve the company&#39;s successor drug to the now defunct pain reliever Vioxx if it provides further safety and
22491
Raymond Gilmartin, chief executive of Merck, will testify before a Senate committee this week on the withdrawal of Vioxx, in spite of efforts by the drug company to send others in his place.
733605
U.S. health officials said on Friday they would review whether to take regulatory action over Merck & Co Inc  and Schering-Plough's  cholesterol medicine Vytorin following the drug's failure to work better than a generic drug in a study of plaque build-up in neck arteries.
285749
Merck & Co. Inc. MRK.N said on  Monday it had received a subpoena from the U.S. Justice  Department and that the Securities and Exchange Commission has  started an informal inquiry concerning its recalled pain  reliever Vioxx.
416045
Merck & Co Inc. is evaluating why  its withdrawn painkiller Vioxx raises the chance of heart  attack and stroke, but it has not found a mechanism of action,  a company official said on Monday.
485027
Drug maker Merck &amp; Co. reported Tuesday that its board appointed a special committee to review the company&#39;s actions before withdrawing blockbuster arthritis drug Vioxx from the market Sept.
66425
London - The European Medicines Agency said on Friday it has been asked by the European Commission to conduct a review of certain arthritis drugs after the worldwide withdrawal of Merck &amp; Company&#39;s Vioxx medication.
55690
U.S. regulators said on Friday they would review whether to take action over Merck & Co Inc's  and Schering-Plough Corp's  popular cholesterol medicine Vytorin after a study showed it was no better than a generic drug in preventing the build-up of fatty plaque.
455886
Drugs in the same category as Merck  & Co. Inc.'s withdrawn Vioxx painkiller will get close scrutiny  to see if they also can cause heart attacks, U.S. regulators  said on Thursday.
361813
The Wall Street Journal has reported that pharmaceutical company Merck knew as far back as 2000 that its arthritis medication, Vioxx, was linked to an increased risk of heart attack.
226044
U.S. health officials said on Friday  they would review whether to take regulatory action over Merck  & Co Inc  and Schering-Plough's  cholesterol  medicine Vytorin following the drug's failure to work better  than a generic drug in a study of plaque build-up in neck  arteries.
34608
GAITHERSBURG, Md.  - U.S. scientific advisers  began hearing evidence on Wednesday about the benefits and  risks of pain killers taken by millions of Americans as  regulators weigh moves following Merck & Co. Inc.'s recall of  its arthritis pill Vioxx.